ADHD Candidate Gene Study in a Population-Based Birth Cohort: Association with DBH and DRD2 - 12/08/11
, STANLEY F. NELSON, M.D., LEENA PELTONEN, M.D., Ph.D.ABSTRACT |
Objective |
Attention-deficit/hyperactivity disorder (ADHD) is a common childhood-onset disorder with a significant impact on public health. Although a genetic contribution to risk is evident, predisposing genetic determinants remain largely unknown despite extensive research. So far, the most promising candidate genes have been those involved in dopamine and serotonin pathways. This study tests a series of allelic variants within such candidate genes to determine their potential influence on ADHD susceptibility.
Method |
We used a population sample ascertained from a birth cohort of a subpopulation of Finland, characterized by founder effect and isolation, thus minimizing genetic heterogeneity. The subjects were systematically ascertained using DSM-IV diagnostic criteria for ADHD from the Northern Finland Birth Cohort 1986 of more than 9,000 individuals, resulting in the study sample of 188 ADHD cases and 166 controls. We genotyped markers in 13 candidate genes, including critical components of dopamine and serotonin pathways.
Results |
We report evidence for association of ADHD with allelic variants of the dopamine β-hydroxylase (DBH) and dopamine receptor D2 (DRD2) genes.
Conclusions |
Our study supports the involvement of the dopamine pathway in the etiology of ADHD; specifically the genes DBH and DRD2 deserve more attention in further studies.
Le texte complet de cet article est disponible en PDF.Key Words : attention-deficit/hyperactivity disorder, birth cohort, DRD2, DBH
Plan
| This research was supported byNational Institute of Mental HealthgrantsMH063706(Smalley, Järvelin) andMH01966(McGough), the Sigrid Juselius Foundation, the Academy of Finland, and Biocentrum Helsinki. Disclosure: Dr. McGough receives grant research support from Eli Lilly, McNeil, New River Pharmaceuticals, Novartis, Shire, and Pfizer, is a consultant to Eli Lilly, Novartis, and Shire, and a member of the speakers’ bureaus of Eli Lilly, McNeil, Novartis, and Shire. Dr. Moilanen is a member of the Lilly Strattera advisory board, Finland. Prof. Peltonen is a board member of Orion Corporation. The other authors have no financial relationships to disclose. |
Vol 46 - N° 12
P. 1614-1621 - décembre 2007 Retour au numéro
Article précédent
- ADHD Symptoms and Subtypes: Relationship Between Childhood and Adolescent Symptoms
- TUULA HURTIG, HANNA EBELING, ANJA TAANILA, JOUKO MIETTUNEN, SUSAN L. SMALLEY, JAMES J. McGOUGH, SANDRA K. LOO, MARJO-RIITTA JÄRVELIN, IRMA K. MOILANEN
- SET-C Versus Fluoxetine in the Treatment of Childhood Social Phobia
- DEBORAH C. BEIDEL, SAMUEL M. TURNER, FLOYD R. SALLEE, ROBERT T. AMMERMAN, LORI A. CROSBY, SANJEEV PATHAK
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?